Scynexis (SCYX) Free Cash Flow (2013 - 2026)
Scynexis' (SCYX) quarterly Free Cash Flow came in at -$14.9 million in Q2 2026, down 98.6% on a YoY basis from -$1.1 billion in Q2 2025, and down 83.74% quarter-over-quarter from -$8.1 million in Q1 2026.
Analysis
Scynexis (SCYX) Free Cash Flow (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Free Cash Flow for 14 consecutive years, with -$14.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Free Cash Flow fell 98.6% year-over-year to -$14.9 million; the trailing twelve-month figure through Jun 2026 stood at -$13.3 million (up 44.78% YoY), and the FY2025 full-year result was -$5.3 million, up 78.0% from the prior year.
- Free Cash Flow slipped to -$14.9 million in Q2 2026 per SCYX's latest filing, from -$8.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $74.4 million in Q2 2023 and bottomed at -$22.8 million in Q4 2022.
- Historically, Free Cash Flow has averaged -$4.0 million across 5 years, with a median of -$8.4 million in 2025.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow sank 1606.3% in 2022, then soared 500.4% in 2023.
- Over 5 years, Free Cash Flow stood at -$22.8 million in 2022, then soared by 66.08% to -$7.7 million in 2023, then dropped by 28.08% to -$9.9 million in 2024, then soared by 285.74% to $18.4 million in 2025, then sank by 180.89% to -$14.9 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$14.9 million, -$8.1 million, and $18.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 3.49 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 3.43 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.01 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 572.80 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -563.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 408.00 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -268.64 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | -14.89 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.89 Mn |
| Mar 31, 2026 | -8.10 Mn |
| Dec 31, 2025 | 18.40 Mn |
| Sep 30, 2025 | -8.72 Mn |
| Jun 30, 2025 | -7.50 Mn |
| Mar 31, 2025 | -7.47 Mn |
| Dec 31, 2024 | -9.91 Mn |
| Sep 30, 2024 | 765,000.00 |
| Jun 30, 2024 | -10.86 Mn |
| Mar 31, 2024 | -4.01 Mn |
| Dec 31, 2023 | -7.74 Mn |
| Sep 30, 2023 | 12.42 Mn |
| Jun 30, 2023 | 74.40 Mn |
| Mar 31, 2023 | -18.92 Mn |
| Dec 31, 2022 | -22.81 Mn |
| Sep 30, 2022 | -22.51 Mn |
| Jun 30, 2022 | -18.58 Mn |
| Mar 31, 2022 | -15.99 Mn |
| Dec 31, 2021 | -25.04 Mn |
| Sep 30, 2021 | -16.82 Mn |